Home/Cyclerion Therapeutics/Michael Higgins

MH

Michael Higgins

Board Member

Cyclerion Therapeutics

Therapeutic Areas

Neuropsychiatry Central Nervous System (CNS)

Cyclerion Therapeutics Pipeline

Drug	Indication	Phase
CYC-126	Treatment-Resistant Depression (TRD)	Phase 1

Leadership Team at Cyclerion Therapeutics

Regina Graul, PhD

President, Chief Executive Officer, Board Member

Rhonda Chicko, CPA

Chief Financial Officer

Errol De Souza, PhD

Chairman of the Board

Peter Hecht, PhD

Steven Hyman, MD

Dina Katabi, PhD

Husseini Manji, MD, FRCPC

Clinical Advisory Board

View full Cyclerion Therapeutics profile